An Open-Label, Extension, Phase II Study to Evaluate the Long-Term Safety and Efficacy of MRA [tocilizumab] in Patients With RA Who Were Participated in Study MRA009JP.

Trial Profile

An Open-Label, Extension, Phase II Study to Evaluate the Long-Term Safety and Efficacy of MRA [tocilizumab] in Patients With RA Who Were Participated in Study MRA009JP.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2013

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 23 Jun 2009 Planned end date changed from 1 Dec 2009 to 1 Jul 2009 as reported by ClinicalTrials.gov.
    • 30 Jan 2009 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov, last updated 30 Jan 2009
    • 18 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top